Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 13132Neoplasms 10477Carcinoma, Non-Small-Cell Lung 6870Prostatic Neoplasms 6268Colorectal Neoplasms 5945Lung Neoplasms 5102Multiple Myeloma 3576Pancreatic Neoplasms 3561Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3507Carcinoma, Hepatocellular 3271Ovarian Neoplasms 3168Melanoma 3139Stomach Neoplasms 3056Lymphoma 2982Head and Neck Neoplasms 2603Recurrence 2556Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2327Brain Neoplasms 2310Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2191Uterine Cervical Neoplasms 2191Glioblastoma 2014Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1847Esophageal Neoplasms 1800

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial Mediterranean Fever × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡